^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gastric Adenocarcinoma
    Drug Class:HER2 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Cancer Res Clin Oncol
    Title:

    HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma

    Published date:
    02/04/2021
    Excerpt:
    The predictive and prognostic value of HER2 amplification in advanced HER2 inhibitor-treated GA patients has been investigated….Patients with high HER2 CN had a significantly shorter DFS than patients with low HER2 CN (p = 0.002).
    DOI:
    10.1007/s00432-021-03522-9